June 2025 in “CA A Cancer Journal for Clinicians” Transgender men need personalized cancer care and continued testosterone therapy for well-being.
559 citations
,
October 2020 in “Frontiers in Molecular Biosciences” Solid lipid nanoparticles are promising for safe and effective drug delivery but need more research for clinical use.
91 citations
,
August 2024 in “Acta Pharmaceutica Sinica B” Microneedles can improve skin disease treatment by delivering drugs directly through the skin.
70 citations
,
May 2023 in “Molecules” Ginkgo biloba has health benefits but also contains toxic compounds, driving interest in its use in medicine and food.
68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” Glibenclamide slows breast cancer cell growth by stopping cell division.
54 citations
,
June 2020 in “Pharmaceutics” New nanocarriers improve drug delivery for disease treatment.
2 citations
,
October 2022 in “Current Allergy and Asthma Reports” Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
1 citations
,
July 2025 in “Stem Cell Research & Therapy” Stem cell technology may improve hair loss treatments by providing more effective and personalized options.
December 2025 in “Pharmaceutics” EV-based drug delivery shows promise but faces challenges in standardization and scalability.
January 2025 in “Applied Sciences” Sulforaphane from broccoli may help treat certain cancers, hormone issues, and hair loss.
January 2025 in “Therapeutic Advances in Medical Oncology” Many young women with breast cancer experience poor quality of life, especially in sexual health and hair loss, but future outlook improves over time.
Many men with androgenic alopecia also have dyslipidemia.
5 citations
,
June 2005 in “Journal of Clinical Oncology” PPX causes much less hair loss than traditional taxanes.
December 2025 in “Drug Design Development and Therapy” Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
400 citations
,
October 1995 in “Journal of clinical oncology” Docetaxel is effective against various cancers but mainly causes neutropenia.
43 citations
,
March 2017 in “Drug Design Development and Therapy” The new nanoparticles could improve melanoma treatment by working better than current options.
February 2006 in “PubMed” Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
63 citations
,
August 2022 in “Diagnostics” Hirsutism can occur in women with PCOS even if their androgen levels are normal, making diagnosis challenging.
March 2025 in “Journal of Medical Research and Surgery” Proper diet, monitoring, and protein supplements are crucial after bariatric surgery to prevent severe malnutrition.
1 citations
,
October 2014 in “Annals of oncology” Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.
9 citations
,
April 2010 in “Lung cancer” Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
20 citations
,
December 2017 in “Cardiovascular diabetology” Linagliptin slows down premature aging in certain mice.
8 citations
,
May 2019 in “Journal of Stem Cells & Regenerative Medicine” Dental pulp stem cells are better for tissue repair, while fat tissue stem cells may be more suited for wound healing and hair growth.
April 2007 in “Nature Clinical Practice Urology” TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.
2 citations
,
May 2011 in “Journal of Clinical Oncology” Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
1 citations
,
January 2012 in “Türk jinekoloji ve obstetrik derneði dergisi/Türk Jinekoloji ve Obstetrik Derneği dergisi” Most patients experienced significant but reversible hair loss during treatment.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.